Evolent Health Inc Cl A Com (EVH) Stock Price, Quote & News

Company Profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated platform for health plan administration and value-based business infrastructure. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system tha...

Industry: Health Information Services

Sector: Healthcare

Phone: 571 389 6000

Website: www.evolent.com

Address:

1812 N. Moore Street, Suite 1705, Arlington, United States

AtomicAIerts Dec. 5 at 10:52 AM

$EVH AtomicAlerts Scalp Alert Direction: LONG Entry: $4.01 TP1: $4.71 | TP2: $5.41 | TP3: $6.11 Stop Loss: $3.41 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 5:53 AM

1ightning® Premium Options Alert (Actionable) Ticker: $EVH Contract: Dec 19 $2.5C Entry: 1.43 Exit: 1.90 Return: +33.28% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Etiqute Dec. 5 at 5:38 AM

$EVH Positive prospects Strong growth momentum: Evolent continues to win new revenue agreements, with the company expecting over $750 million in new annualized revenue to launch in 2026. Focus on high-demand areas: The company is strategically targeting the oncology market, which presents significant growth potential, and is launching new solutions to enhance its oncology capabilities. Value-based care: Evolent's momentum in value-based care and strategic moves, such as the acquisition of NIA, are contributing to positive investor sentiment. Analyst ratings: Some analysts maintain a bullish "Buy" rating on the stock, citing strong growth prospects and strategic positioning. AI and technology: The company is advancing its use of AI-driven healthcare technology, which could enhance its competitive edge.

0 · Reply

Etiqute Dec. 5 at 5:37 AM

$EVH Analyst sentiment Mixed price targets: Analyst price targets are varied, with some ranging significantly higher than the current stock price, while others have recently been reduced. Divergent ratings: While some analysts maintain a "Buy" rating, other reports suggest a more cautious or neutral outlook due to the identified risks. Investor sentiment: Recent share price movements reflect a complex mix of factors, with some viewing the recent decline as a potential buying opportunity and others more concerned about future risks.

0 · Reply

Etiqute Dec. 5 at 5:34 AM

$EVH Challenges and risks Intensifying competition: Evolent faces increasing competition from other digital health companies, which threatens its market position. Regulatory scrutiny: Heightened regulatory oversight poses a risk to the company's pricing and earnings stability. Client concentration: A high concentration of its client base presents a risk, as does the potential for clients to bring services in-house ("internalization"). Earnings shortfalls: Recent quarterly reports have shown an earnings-per-share (EPS) shortfall compared to analyst expectations, although revenue targets were exceeded. Uncertainty in membership: Uncertainties in membership numbers, particularly in Medicare Advantage, could impact future earnings.

0 · Reply

Etiqute Dec. 5 at 5:31 AM

$EVH Evolent Health's prospects are mixed, with a strong growth outlook driven by new contract wins, a focus on high-demand areas like oncology, and increasing value-based care momentum, offset by challenges like intensifying competition, potential client internalization, and regulatory headwinds. While analysts see potential upside and some maintain a "Buy" rating, others point to risks that could impact its financial performance and market position.

0 · Reply

Iightning Dec. 4 at 11:42 PM

1ightning® Premium Options Alert (Actionable) Ticker: $EVH Contract: Dec 19 $2.5C Entry: 1.43 Exit: 1.90 Return: +33.28% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

PHILMYWALLET Dec. 4 at 9:45 PM

$EVH it has to break that $4.10 barrier and we're back to an upward trend

0 · Reply

riedela Dec. 4 at 9:13 PM

$EVH Hopefully, that's the last of 3 dollars and something BS. Trump has hinted at 2 year temp Obamacare subsidies with strings. Sounds about right.

0 · Reply

tigres1005 Dec. 4 at 8:33 PM

$EVH I'll be shocked if share price hasn't doubled by Feb earnings report.

1 · Reply

Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 2:46 PM EST - 27 days ago

Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:12 PM EST - 4 weeks ago

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

Nov 6, 2025, 4:10 PM EST - 4 weeks ago

Evolent Announces Third Quarter 2025 Results

Oct 9, 2025, 8:30 AM EDT - 2 months ago

Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Sep 23, 2025, 4:10 PM EDT - 2 months ago

Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

PRVA

Aug 21, 2025, 8:35 AM EDT - 3 months ago

Evolent's Soft Q2 Results: Why I'm Holding Anyway

Aug 19, 2025, 7:00 AM EDT - 3 months ago

Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 18, 2025, 4:05 PM EDT - 3 months ago

Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 8, 2025, 6:15 PM EDT - 4 months ago

Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:08 PM EDT - 4 months ago

EVH Earnings Drop 31%

Aug 7, 2025, 4:10 PM EDT - 4 months ago

Evolent Announces Second Quarter 2025 Results

Jul 14, 2025, 8:00 AM EDT - 5 months ago

Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Evolent announces key appointments to leadership team

Jun 20, 2025, 6:30 AM EDT - 6 months ago

Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

May 9, 2025, 6:03 PM EDT - 7 months ago

Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 7 months ago

Evolent Announces First Quarter 2025 Results

Apr 22, 2025, 6:30 AM EDT - 8 months ago

Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 8 months ago

Evolent program achieves 20% reduction in use of low-value oncology regimens

Apr 10, 2025, 5:00 PM EDT - 8 months ago

Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025

Feb 20, 2025, 7:28 PM EST - 10 months ago

Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:10 PM EST - 10 months ago

Evolent Announces Fourth Quarter and Full Year 2024 Results

Feb 4, 2025, 7:00 AM EST - 10 months ago

Evolent Health Announces Changes to Board of Directors

Jan 27, 2025, 5:00 PM EST - 11 months ago

Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025

Dec 18, 2024, 4:10 PM EST - 1 year ago

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Nov 12, 2024, 2:37 AM EST - 1 year ago

Evolent Health: A Shot At Revival After Market Bruising

Nov 9, 2024, 9:12 AM EST - 1 year ago

Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:47 AM EST - 1 year ago

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

PINS RDFN SG

Nov 7, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Third Quarter 2024 Results

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 2, 2024, 12:08 PM EDT - 1 year ago

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Aug 23, 2024, 9:00 AM EDT - 1 year ago

Evolent Health: Let The Bidding Begin

Aug 22, 2024, 1:22 PM EDT - 1 year ago

Exclusive: Evolent Health in sale talks after inbound interest, sources say

Aug 8, 2024, 9:18 PM EDT - 1 year ago

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces Second Quarter 2024 Results

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 4, 2024, 7:00 AM EDT - 1 year ago

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

May 9, 2024, 4:15 PM EDT - 1 year ago

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

May 9, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces First Quarter 2024 Results

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Feb 22, 2024, 10:34 PM EST - 1 year ago

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Fourth Quarter and Full Year 2023 Results

Feb 14, 2024, 4:10 PM EST - 1 year ago

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

Jan 25, 2024, 7:00 AM EST - 2 years ago

Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024

Dec 5, 2023, 10:59 PM EST - 2 years ago

Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan

Dec 5, 2023, 7:00 AM EST - 2 years ago

Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan

Nov 4, 2023, 3:13 AM EDT - 2 years ago

Evolent Health, Inc. (EVH) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:10 PM EDT - 2 years ago

Evolent Announces Third Quarter 2023 Results

Oct 10, 2023, 5:30 PM EDT - 2 years ago

Evolent to release third quarter financial results on Thursday, Nov. 2, 2023, and participate in upcoming investor conferences

Oct 4, 2023, 3:16 PM EDT - 2 years ago

A First Evaluation On Evolent Health

AtomicAIerts Dec. 5 at 10:52 AM

$EVH AtomicAlerts Scalp Alert Direction: LONG Entry: $4.01 TP1: $4.71 | TP2: $5.41 | TP3: $6.11 Stop Loss: $3.41 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 5:53 AM

1ightning® Premium Options Alert (Actionable) Ticker: $EVH Contract: Dec 19 $2.5C Entry: 1.43 Exit: 1.90 Return: +33.28% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Etiqute Dec. 5 at 5:38 AM

0 · Reply

Etiqute Dec. 5 at 5:37 AM

0 · Reply

Etiqute Dec. 5 at 5:34 AM

0 · Reply

Etiqute Dec. 5 at 5:31 AM

0 · Reply

Iightning Dec. 4 at 11:42 PM

1ightning® Premium Options Alert (Actionable) Ticker: $EVH Contract: Dec 19 $2.5C Entry: 1.43 Exit: 1.90 Return: +33.28% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

PHILMYWALLET Dec. 4 at 9:45 PM

$EVH it has to break that $4.10 barrier and we're back to an upward trend

0 · Reply

riedela Dec. 4 at 9:13 PM

$EVH Hopefully, that's the last of 3 dollars and something BS. Trump has hinted at 2 year temp Obamacare subsidies with strings. Sounds about right.

0 · Reply

tigres1005 Dec. 4 at 8:33 PM

$EVH I'll be shocked if share price hasn't doubled by Feb earnings report.

1 · Reply

PHILMYWALLET Dec. 4 at 6:35 PM

$EVH when are insiders going to double down? Seth, Dan, Katie, Felicia, John, Johnathan, Andrew, David, Emily,.....start buying please! PLEASE SAVE US

0 · Reply

PHILMYWALLET Dec. 4 at 6:27 PM

$EVH I prefer this one. Can't wait 🥳

0 · Reply

riedela Dec. 4 at 5:04 PM

$EVH More like...

1 · Reply

PHILMYWALLET Dec. 4 at 3:21 PM

$EVH since I am the only one posting on this board, here for you . Is that explicit enough?

0 · Reply

Iightning Dec. 4 at 7:21 AM

1ightning® Premium Options Alert (Actionable) Ticker: $EVH Contract: Dec 19 $2.5C Entry: 1.38 Exit: 2.15 Return: +56.72% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

tigres1005 Dec. 3 at 3:52 PM

$CAPR Phenomenal day, sold @ $34.81 average. Will take some proceeds to purchase more of $SLS, $EVH, $CRVO and back into $CAPR when price settles.

0 · Reply

PHILMYWALLET Dec. 2 at 9:59 PM

$EVH I'm happy with holding. A director bought 10,000 shares on Nov 18, 2025, at about $3.82/share. Back in March 2025, a broad batch of insiders — including CEO, board directors and the president — bought shares in open-market transactions. For instance: CEO bought 55,225 shares around $9.01–9.33. Directors (e.g. Richard Jelinek, Diane Holder, others) added shares. According to one summary site, insiders bought a total of ~94,000 EVH shares over the last 24 months — worth about $742,715 — and no large aggregated sales are flagged for 2025 in that dataset. So: there is recent insider buying — including a purchase just a few weeks ago

1 · Reply

PHILMYWALLET Dec. 2 at 9:50 PM

$EVH Jill Smith will help get this company back on track. Jill Smith will serve a term expiring at the 2026 annual meeting. She brings over 25 years of business leadership experience, including 17 years as chief executive officer of private and public technology companies and more than a decade as an independent director.

0 · Reply

JarvisFlow Dec. 2 at 6:53 PM

Truist Securities has adjusted their stance on Evolent Health ( $EVH ), setting the rating to Hold with a target price of 34 → 28.

0 · Reply

riedela Dec. 2 at 6:51 PM

$EVH Man, I am wrong on this one. Big sell during Trump's cabinet meeting. I am down over 300k but added today. 🙄

1 · Reply

riedela Dec. 2 at 5:52 PM

$EVH Trump didn't help today by accusing Healthcare getting rich by charging too much... (Not a lie) but damn. During cabinet meeting today, he said it again and we dropped from green to ugly red. ☠️

0 · Reply

riedela Dec. 2 at 2:43 PM

$EVH Longs will profit from the likely Extension of ACA subsidies very soon. Shares are being robbed from the weak and millions will be made in health sector stocks when the white house pushes a compromise.

0 · Reply

Market Cap	433.01M
Revenue (ttm)	2.55B
Net Income (ttm)	-61.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.41%
Debt to Equity Ratio	1.25

Volume	4,581,200
Avg Vol	3,764,714
Day's Range	N/A - N/A
Shares Out	111.60M
Stochastic %K	33%
Beta	0.28
Analysts	Strong Sell
Price Target	$10.18